• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bexson Biomedical wins U.S. patent for ketamine formulation

April 30, 2021 By Sean Whooley

Bexson Biomedical Ketamine Pump
Bexson is developing a wearable ketamine pump with Stevanato Group. (Image from Bexson)

Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy.

Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the subcutaneous route, according to a news release.

The patent applies to Bexson’s ketamine formulation tuned to the pH and osmolality of subcutaneous tissue. At the same time, it also applies to racemic ketamine and the R or S enantiomers as Bexson seeks to enable its subcutaneous ketamine delivery platform designed to manage pain disorders and mental health conditions.

Bexson and the FDA are currently working together as the company prepares for clinical trials that will evaluate the subcutaneous delivery of its ketamine formula, while it partnered with Stevanato Group to develop a wearable patch pump to allow for controlled delivery from a pre-filled, pre-sterilized wearable device.

Other formulation applications include further non-oral delivery solutions, like new chemical entities and research chemicals in the psychedelic medicine space.

“This technology provides a great new benefit for patients. We believe that the subcutaneous route of administration is perhaps the best method to deliver a controlled substance in a controlled manner,” Bexson co-founder & CSO Dr. Jeffrey Becke said in the release. “Ketamine is just one compound to which we can apply our formulation technology. We look forward to developing additional therapies to improve the viability of exciting controlled substances, including psychedelics and empathogens, for health conditions like chronic pain, addiction, PTSD and depression.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Bexson Biomedical, Stevanato Group

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS